FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539465> ?p ?o ?g. }

• W4318539465 endingPage "i552" @default.
• W4318539465 startingPage "i551" @default.
• W4318539465 abstract "Abstract Background Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn’s Disease (CD), is a group of chronic inflammatory disorders. Biologics are indicated for patients failing conventional maintenance therapy with moderate to severe activity. Different routes of administration, intravenous (IV), subcutaneous (SC) or oral have been approved. For chronic diseases such as IBD, some patients may prefer self-administered SC dosing to IV dosing as a less time-intensive and more convenient treatment option. This aims to assess acceptance, safety and satisfaction of transition from IV to SC administration of infliximab (IFX) and vedolizumab (VDZ) in cohort of patients with IBD. Methods The transition from IV to SC administration was proposed to 91 patients. All patients were given two questionnaire: (a) before the switch, focused on the impact of the IV administration on their life and (b) 8 weeks after the switch focused on the level of satisfaction and onset of adverse event (AE). Data on medical history and treatment was collected from electronic health records. Results Overall, 91 patients were enrolled for switching from IV to SC therapy. All patients filled the first questionnaire. The IV therapy did not or minimally burden on patients’ life in 71% and 15 patients (16%) refused the transition. The main reasons why patients preferred to stay on IV administration were the fear of reducing follow-up visit with IBD staff and the fear of doing the therapy outside the hospital. On the other hand, 76 patients accepted and 8 weeks after the transition they completed the second questionnaire. of these 76, 39 CD and 51 male, 41 (53%) were treated with VDZ and the majority of patients (53%) were at the first line of treatment. Most of patients (67%) did not experience any difficulties in handling the device but “only” the 65% respected the correct time-table of administration. 20% of patients report at least one AE, the most common were erythema, swelling and pain in the injection site. Only the 5% should switch back to IV treament. 8 patients (10%) were switched back to IV administration due to AEs and 1 swaped to Ustekinumab. Conclusion In this cohort of IBD patients, we found a good acceptance rate (83.5%). The vast majority of patients (95%) was satisfied of transition from IV to SC. Moreover, we reported a good safety profile of SC therapy, AEs were mostly self-limited and local." @default.
• W4318539465 created "2023-01-31" @default.
• W4318539465 creator A5013933716 @default.
• W4318539465 creator A5014964540 @default.
• W4318539465 creator A5021794119 @default.
• W4318539465 creator A5055467729 @default.
• W4318539465 creator A5073929741 @default.
• W4318539465 date "2023-01-30" @default.
• W4318539465 modified "2023-09-29" @default.
• W4318539465 title "P422 Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease" @default.
• W4318539465 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0552" @default.
• W4318539465 hasPublicationYear "2023" @default.
• W4318539465 type Work @default.
• W4318539465 citedByCount "0" @default.
• W4318539465 crossrefType "journal-article" @default.
• W4318539465 hasAuthorship W4318539465A5013933716 @default.
• W4318539465 hasAuthorship W4318539465A5014964540 @default.
• W4318539465 hasAuthorship W4318539465A5021794119 @default.
• W4318539465 hasAuthorship W4318539465A5055467729 @default.
• W4318539465 hasAuthorship W4318539465A5073929741 @default.
• W4318539465 hasBestOaLocation W43185394651 @default.
• W4318539465 hasConcept C126322002 @default.
• W4318539465 hasConcept C197934379 @default.
• W4318539465 hasConcept C2776207728 @default.
• W4318539465 hasConcept C2777138892 @default.
• W4318539465 hasConcept C2777288759 @default.
• W4318539465 hasConcept C2778260677 @default.
• W4318539465 hasConcept C2779134260 @default.
• W4318539465 hasConcept C2780479503 @default.
• W4318539465 hasConcept C71924100 @default.
• W4318539465 hasConcept C72563966 @default.
• W4318539465 hasConceptScore W4318539465C126322002 @default.
• W4318539465 hasConceptScore W4318539465C197934379 @default.
• W4318539465 hasConceptScore W4318539465C2776207728 @default.
• W4318539465 hasConceptScore W4318539465C2777138892 @default.
• W4318539465 hasConceptScore W4318539465C2777288759 @default.
• W4318539465 hasConceptScore W4318539465C2778260677 @default.
• W4318539465 hasConceptScore W4318539465C2779134260 @default.
• W4318539465 hasConceptScore W4318539465C2780479503 @default.
• W4318539465 hasConceptScore W4318539465C71924100 @default.
• W4318539465 hasConceptScore W4318539465C72563966 @default.
• W4318539465 hasIssue "Supplement_1" @default.
• W4318539465 hasLocation W43185394651 @default.
• W4318539465 hasOpenAccess W4318539465 @default.
• W4318539465 hasPrimaryLocation W43185394651 @default.
• W4318539465 hasRelatedWork W2790575954 @default.
• W4318539465 hasRelatedWork W2793717011 @default.
• W4318539465 hasRelatedWork W2802577932 @default.
• W4318539465 hasRelatedWork W2802584626 @default.
• W4318539465 hasRelatedWork W2913273475 @default.
• W4318539465 hasRelatedWork W2923211281 @default.
• W4318539465 hasRelatedWork W2944664811 @default.
• W4318539465 hasRelatedWork W4200397779 @default.
• W4318539465 hasRelatedWork W4282048809 @default.
• W4318539465 hasRelatedWork W4323355719 @default.
• W4318539465 hasVolume "17" @default.
• W4318539465 isParatext "false" @default.
• W4318539465 isRetracted "false" @default.
• W4318539465 workType "article" @default.